Patent ID: 9321843
Filing Date: 2016-04-26
CPC Classification: A61K,A61P,C07K,C12N,C12P,Y02P

Claim Text:
1. A method of treating an autoimmune disease or disorder based on B-cell depletion in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a composition comprising a glycoengineered anti-CD20 antigen binding molecule, wherein said glycoengineered anti-CD20 antigen binding molecule comprises an immunoglobulin G (IgG) Fc region containing N-linked oligosaccharides, wherein said glycoengineered anti-CD20 antigen binding molecule has an increased ratio of GlcNAc residues to fucose residues in the Fc region compared to a corresponding anti-CD20 antigen binding molecule that has not been glycoengineered, and wherein said glycoengineered anti-CD20 antigen binding molecule has increased Fc-mediated cellular cytotoxicity compared to a corresponding anti-CD20 antigen binding molecule that has not been glycoengineered.